tiprankstipranks
Bristol-Myers Squibb Company (MX:BMY)
NYSE:BMY
Mexico Market
BMY
Bristol-Myers Squibb
RESEARCH TOOLSreports

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

BMY Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
7 Buy
10 Hold
1 Sell
Based on 18 analysts giving stock ratings to
Bristol-Myers
Squibb
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$1,108.53
Based on 18 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $1,108.53 with a high forecast of $1,313.16 and a low forecast of $700.35. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"699":"$699","1314":"$1,314","852.75":"$852.8","1006.5":"$1,006.5","1160.25":"$1,160.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1313.16314775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1108.528557225625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":700.3536787999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$700.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[699,852.75,1006.5,1160.25,1314],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,963.496,990.3934729038461,1017.2909458076923,1044.1884187115384,1071.0858916153845,1097.9833645192307,1124.8808374230769,1151.778310326923,1178.6757832307692,1205.5732561346153,1232.4707290384615,1259.3682019423077,1286.2656748461538,{"y":1313.16314775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,963.496,974.6523505558173,985.8087011116346,996.9650516674519,1008.1214022232692,1019.2777527790865,1030.4341033349037,1041.5904538907212,1052.7468044465386,1063.9031550023558,1075.059505558173,1086.2158561139904,1097.3722066698078,{"y":1108.528557225625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,963.496,943.2542829846153,923.0125659692308,902.7708489538461,882.5291319384614,862.2874149230769,842.0456979076922,821.8039808923077,801.562263876923,781.3205468615383,761.0788298461538,740.8371128307691,720.5953958153846,{"y":700.3536787999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":818.834,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":810.431,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":835.697,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":824.751,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":821.528,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":863.087,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":941.374,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":919.74,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1048.782,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1090.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1039.132,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":993.652,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":963.496,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,313Average Price Target$1,109Lowest Price Target$700.35
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:BMY
Courtney Breen
Bernstein
Bernstein
$1,015.51
Hold
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Avantor (NYSE: AVTR) and Bristol-Myers Squibb (NYSE: BMY)
Goldman Sachs Analyst forecast on MX:BMY
Asad Haider
Goldman Sachs
Goldman Sachs
$1,068.04
Hold
―
Reiterated
07/20/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Bristol-Myers Squibb (NYSE: BMY) and Peptidream (Other OTC: PPTDF)
Citi Analyst forecast on MX:BMY
Geoff Meacham
Citi
Citi
$1,155.58
Hold
―
Reiterated
07/15/26
Bristol-Myers Squibb (BMY) Receives a Hold from Citi
Wells Fargo Analyst forecast on MX:BMY
Mohit Bansal
Wells Fargo
Wells Fargo
$1,050.53
Hold
―
Reiterated
07/13/26
Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
BMO Capital Analyst forecast on MX:BMY
Evan Seigerman
BMO Capital
BMO Capital
$1,050.53
Hold
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), NovoCure (NASDAQ: NVCR) and Bristol-Myers Squibb (NYSE: BMY)
Bank of America Securities Analyst forecast on MX:BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,173.09→$1,155.58
Buy
―
Reiterated
07/10/26
Bank of America Securities Remains a Buy on Bristol-Myers Squibb (BMY)
RBC Capital Analyst forecast on MX:BMY
Trung Huynh
RBC Capital
RBC Capital
$1,050.53
Hold
―
Reiterated
07/10/26
RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Guggenheim Analyst forecast on MX:BMY
Seamus Fernandez
Guggenheim
Guggenheim
$1,260.64
Buy
―
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Bristol-Myers Squibb (NYSE: BMY) and Delcath Systems (NASDAQ: DCTH)
Scotiabank Analyst forecast on MX:BMY
Louise Chen
Scotiabank
Scotiabank
$1,050.53
Hold
―
Reiterated
07/09/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY) and SELLAS Life Sciences Group (NASDAQ: SLS)
Piper Sandler Analyst forecast on MX:BMY
David Amsellem
Piper Sandler
Piper Sandler
$1,313.16
Buy
―
Reiterated
06/03/26
Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler
UBS Analyst forecast on MX:BMY
Michael Yee
UBS
UBS
$1,225.62
Buy
―
Reiterated
06/03/26
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
Barclays Analyst forecast on MX:BMY
Emily Field
Barclays
Barclays
$1,313.16
Buy
―
Reiterated
06/02/26
Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
Jefferies Analyst forecast on MX:BMY
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$1,225.62→$1,278.15
Buy
―
Reiterated
06/01/26
Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Morgan Stanley Analyst forecast on MX:BMY
Terence Flynn
Morgan Stanley
Morgan Stanley
$700.35
Sell
―
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX), Bristol-Myers Squibb (NYSE: BMY) and Pelthos Therapeutics (NYSE MKT: PTHS)
TD Cowen Analyst forecast on MX:BMY
Unknown Analyst
TD Cowen
Not Ranked
TD Cowen
$998
Hold
―
Reiterated
05/18/26
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:BMY
Courtney Breen
Bernstein
Bernstein
$1,015.51
Hold
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Avantor (NYSE: AVTR) and Bristol-Myers Squibb (NYSE: BMY)
Goldman Sachs Analyst forecast on MX:BMY
Asad Haider
Goldman Sachs
Goldman Sachs
$1,068.04
Hold
―
Reiterated
07/20/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Bristol-Myers Squibb (NYSE: BMY) and Peptidream (Other OTC: PPTDF)
Citi Analyst forecast on MX:BMY
Geoff Meacham
Citi
Citi
$1,155.58
Hold
―
Reiterated
07/15/26
Bristol-Myers Squibb (BMY) Receives a Hold from Citi
Wells Fargo Analyst forecast on MX:BMY
Mohit Bansal
Wells Fargo
Wells Fargo
$1,050.53
Hold
―
Reiterated
07/13/26
Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
BMO Capital Analyst forecast on MX:BMY
Evan Seigerman
BMO Capital
BMO Capital
$1,050.53
Hold
―
Reiterated
07/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), NovoCure (NASDAQ: NVCR) and Bristol-Myers Squibb (NYSE: BMY)
Bank of America Securities Analyst forecast on MX:BMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$1,173.09→$1,155.58
Buy
―
Reiterated
07/10/26
Bank of America Securities Remains a Buy on Bristol-Myers Squibb (BMY)
RBC Capital Analyst forecast on MX:BMY
Trung Huynh
RBC Capital
RBC Capital
$1,050.53
Hold
―
Reiterated
07/10/26
RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Guggenheim Analyst forecast on MX:BMY
Seamus Fernandez
Guggenheim
Guggenheim
$1,260.64
Buy
―
Reiterated
07/09/26
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (NASDAQ: ANIP), Bristol-Myers Squibb (NYSE: BMY) and Delcath Systems (NASDAQ: DCTH)
Scotiabank Analyst forecast on MX:BMY
Louise Chen
Scotiabank
Scotiabank
$1,050.53
Hold
―
Reiterated
07/09/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY) and SELLAS Life Sciences Group (NASDAQ: SLS)
Piper Sandler Analyst forecast on MX:BMY
David Amsellem
Piper Sandler
Piper Sandler
$1,313.16
Buy
―
Reiterated
06/03/26
Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler
UBS Analyst forecast on MX:BMY
Michael Yee
UBS
UBS
$1,225.62
Buy
―
Reiterated
06/03/26
Bristol-Myers Squibb: Emerging Oncology Portfolio Supports Durable Growth; Buy Rating Reiterated with Unchanged $70 Price Target
Barclays Analyst forecast on MX:BMY
Emily Field
Barclays
Barclays
$1,313.16
Buy
―
Reiterated
06/02/26
Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
Jefferies Analyst forecast on MX:BMY
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$1,225.62→$1,278.15
Buy
―
Reiterated
06/01/26
Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Morgan Stanley Analyst forecast on MX:BMY
Terence Flynn
Morgan Stanley
Morgan Stanley
$700.35
Sell
―
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX), Bristol-Myers Squibb (NYSE: BMY) and Pelthos Therapeutics (NYSE MKT: PTHS)
TD Cowen Analyst forecast on MX:BMY
Unknown Analyst
TD Cowen
Not Ranked
TD Cowen
$998
Hold
―
Reiterated
05/18/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
GKOSGlaukos
MGTXMeiragtx Holdings
TECXTectonic Therapeutic
STOKStoke Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

3 Months
Srikripa DevarakondaTruist Financial
Success Rate
12/15 ratings generated profit
80%
Average Return
+10.07%
Copying Srikripa Devarakonda's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +10.07% per trade.
1 Year
Srikripa DevarakondaTruist Financial
Success Rate
13/15 ratings generated profit
87%
Average Return
+16.43%
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +16.43% per trade.
2 Years
Srikripa DevarakondaTruist Financial
Success Rate
15/15 ratings generated profit
100%
Average Return
+29.30%
Copying Srikripa Devarakonda's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
16
13
14
19
15
Hold
27
27
30
27
23
Sell
2
1
1
1
1
Strong Sell
0
0
0
0
0
total
45
41
45
47
39
In the current month, BMY has received 15 Buy Ratings, 23 Hold Ratings, and 1 Sell Ratings. BMY average Analyst price target in the past 3 months is 1,108.53.
Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $27.94 with a range of $25.98 to $29.41. The previous quarter’s EPS was $27.66. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s earnings estimate for BMY is $27.94 with a range of $25.98 to $29.41. The previous quarter’s EPS was $27.66. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $205.58B with a range of $201.52B to $210.08B. The previous quarter’s sales results were $201.16B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.
Next quarter’s sales forecast for BMY is $205.58B with a range of $201.52B to $210.08B. The previous quarter’s sales results were $201.16B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Stock Forecast FAQ

What is MX:BMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Bristol-Myers Squibb Company’s 12-month average price target is 1,108.53.
    What is MX:BMY’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:BMY, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Bristol-Myers Squibb Company a Buy, Sell or Hold?
        Bristol-Myers Squibb Company has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 10 hold ratings and 1 sell ratings.
          What is Bristol-Myers Squibb Company’s share price target?
          The average share price target for Bristol-Myers Squibb Company is 1,108.53. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $1,313.16 ,and the lowest forecast is $700.35. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Bristol-Myers Squibb Company?
            Bristol-Myers Squibb Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
              How can I buy shares of Bristol-Myers Squibb Company?
              To buy shares of MX:BMY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.